Ivabradina Aurovitas (Ivabradine Hydrochloride)

Ivabradine, the active ingredient in Ivabradina Aurovitas, is a If channel inhibitor presented as an oral tablet for oral use. It is indicated for chronic stable angina and heart failure with reduced ejection fraction in appropriate adult patients.

GNH USA supplies Ivabradina Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradina Aurovitas acts on the cardiac If current to manage conditions where heart‑rate reduction is therapeutic.

- Chronic stable angina: reduces frequency of angina attacks and improves exercise tolerance. - Heart failure with reduced ejection fraction: lowers heart rate, improving symptoms and decreasing hospitalisations. - Inappropriate sinus tachycardia: helps control elevated resting heart rate.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects: - Bradycardia: heart rate slower than intended. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Fatigue or weakness. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical attention. - Atrial fibrillation or other arrhythmias. - Severe visual impairment. - Allergic reactions such as rash or angioedema. - Hypotension leading to syncope. - Hepatic enzyme elevations.

Before initiating ivabradine, consider the following safety measures.

- Cardiac monitoring: assess baseline heart rate and rhythm. - Concomitant bradycardic agents: avoid excessive heart‑rate lowering. - Severe hepatic impairment: use with caution or avoid. - Pregnancy: safety not established; weigh benefits against risks. - Drug interactions: review concomitant CYP3A4 inhibitors or inducers. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Ivabradine may interact with several medicines; monitor accordingly.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin): reduce ivabradine efficacy. - Other potent bradycardic agents (high‑dose beta‑blockers, digoxin): risk of severe bradycardia.

Moderate Interactions (Monitor Closely): - Verapamil or diltiazem: may raise ivabradine concentrations. - Amiodarone: potential increase in plasma levels. - CYP3A4‑modulating antidepressants (e.g., fluoxetine): require monitoring of heart rate.